QX030N (CLD-423) is a clinical-stage long-acting bispecific antibody targeting the clinically validated IL-23p19 and TL1A Pathways. Combining these two powerful autoimmune targets in a single molecule represents the next frontier in IBD treatment. QX030N/CLD-423 is rationally designed to achieve a best-in-disease profile with optimized efficacy, safety, pharmacokinetics and developability. In January 2026, the overseas Phase I clinical trial of QX030N in healthy volunteers has completed the dosing of the first subjects.

On April 23, 2025, the Company and Caldera Therapeutics entered into an out-license agreement (the “License Agreement”). The License Agreement has granted Caldera Therapeutics an exclusive right to develop and commercialize QX030N/CLD-423 globally. In return, Qyuns will be entitled to receive a one-time, non-refundable, and non-creditable upfront payment of USD$10 million, and to receive part of the equity interest in Caldera Therapeutics. Qyuns may also receive additional payments of up to USD$545 million, subject to the achievement of certain clinical development, regulatory and commercial milestones. The Group will also be entitled to receive tiered royalties on net sales from Caldera Therapeutics during a specified time period after the first commercial sales of QX030N.